ID: MRFR/MED/5481-HCR | February 2021 | Region: Global | 90 pages
Drug Device Combination market is expected to register a CAGR of 11.4% during the forecast period of 2018 to 2023. In this market, products that comprises of more than two regulated components, i.e., drug and device are considered. Such devices are extensively utilized for therapeutic purposes against diseases like cardiovascular diseases. From the past few years, the global burden of the diseases like cardiovascular diseases, urology diseases, and others have increased. This provided suitable backgrounds for the market to develop and grow. According to the factsheet of 2017 published by the Centers for Disease Control and Prevention it was estimated that ~610,000 people within the U.S. die from heart diseases. Moreover, it is mentionable that from the past few years, the reported cases of urology diseases have increased. According to the cancer research UK, there were ~47,151 new cases of prostate cancer within the region. This is estimated to significantly increase the demand for drug devices for the related therapeutics, enabling the drug device combination market to grow.
Additionally, factors such as growing healthcare expenditure, rising awareness for the disease, and increasing R&D expenses by the key players drives the global drug device combination market. However, side effects, high cost of the products, and presence of low income countries within the developing regions restricts the market growth. It has been reported that products like Cypher causes thrombosis.
Drug Device Combination Market Segmentation:
The drug device combination market is segmented based on product, application, end user and region. Based on product, the market is segmented into catheter, advanced wound care products, and others. The catheter segment is sub-segmented into antimicrobial catheter, urological catheters, cardiovascular catheters, oximetry catheters, thermodilution catheters, wound drainage catheter, and others. The advanced wound care products segment is sub-divided into antibiotic wound care, bone graft substitutes, antibiotic bone cements, drug eluting stents, photodynamic therapy. The bone graft substitutes segment is sub-segmented into ceramic based bone graft substitute, allograft-based bone graft substitutes, cell-based bone graft substitutes, and others. On the basis of application, the market is devised into coronary angioplasty, tachycardia management, non-cardiovascular treatments, peripheral arterial disease (pad), bone treatment, antimicrobial applications, wound care, ophthalmic treatment, and others. By end user, the drug device combination market is divided into hospitals & clinics, ambulatory centres, and academic & research organization, and others. In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely- the Americas, Europe, Asia-Pacific and the Middle East & African region.
Regional Market Summary
Global Drug Device Combination Share (%), by Region, 2017
The Americas dominated the drug device combination market owing to rising prevalence of cardiovascular diseases and presence of major market players within the region. Additionally, suitable reimbursement policies, high healthcare expenditure, and developed healthcare sector in the U.S. and Canada boost the market to grow. In 2017, it was estimated that Europe stood second in the global drug device combination owing to the to the presence of a well-developed healthcare infrastructure, increasing awareness for the devices within the region and presence of developed economies within the region. Additionally, a large patient pool boosts the drug device combination market.
Asia Pacific was projected to be the fastest growing region in 2017. This can be attributed due to the increasing penetration of the market players within the region, growing healthcare sector and increasing government support for foreign investments. According to a report published by the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was estimated to grow at a CAGR of 22.87 and reach USD 280 billion by 2020.
On the other hand, the Middle East and Africa held least share in the Global Drug Device Combination Market due to the presence of poor economies and low per capita income, especially within the African region. The Middle Eastern region is estimated to be a major market for the Middle East and African region. This can be attributed due to increasing government funding in the healthcare followed by the presence of developed economies like United Arab Emirates, Saudi Arabia, Dubai, and others within the regional boundaries of the region.
Drug Device Combination Market Key players:
Some of the key players in the drug device combination market are 3M, Abbott Laboratories, AlloSource, Biomet Orthopedics, Inc., Biometrix Medical, Biotronik, Boston Scientific Corporation, C.R. BARD, Inc., Cook Critical Care, Inc., Covidien Ltd, Smith & Nephew Plc, St. Jude Medical Inc, Stryker Corporation, Wright Medical Group, Inc., Zimmer Holding, Inc., and others.
Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analysing historical trends and current drug device combination market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
Extensive primary research was conducted to gain a deeper insight of the market and the industry performance. In this particular report we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for extensive, technical, market-oriented, and commercial study of the drug device combination. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company web sites, international organization of chemical manufacturers, some paid databases, and many others.
Global Drug Device Combination Market, by Product:
Global Drug Device Combination Market, by Application:
Global Drug Device Combination Market, by End User
Frequently Asked Questions (FAQ) :
Drug Device Combination Market has a growth opportunity with an 11.4% CAGR during the forecast period of 2018 to 2023.
Americas would dominate the global Drug Device Combination Market.
Asia Pacific regional Drug Device Combination Market would be the fastest-growing among all the regions.
Drug Device Combination Market has players like AlloSource, 3M, Abbott Laboratories, Biometrix Medical, Biotronik, C.R. BARD, Boston Scientific Corporation, Biomet Orthopedics, Inc., Inc., Covidien Ltd, Cook Critical Care, Inc., St. Jude Medical Inc, Smith & Nephew Plc, Zimmer Holding, Inc., Stryker Corporation, Wright Medical Group, Inc., and others.
Drug Device Combination Market would be triggered by end users like academic & research organizations, ambulatory centers, hospitals & clinics, and others.